{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:37:41Z","timestamp":1773772661652,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.vaccine.2014.04.084","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T19:15:54Z","timestamp":1399662954000},"page":"3982-3988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults"],"prefix":"10.1016","volume":"32","author":[{"given":"Mark","family":"Hatherill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Geldenhuys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Pienaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phalkun","family":"Chheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Debanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Hoft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Henry","family":"Boom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem A.","family":"Hanekom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0005","doi-asserted-by":"crossref","first-page":"e1001012","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG World Atlas: a database of global BCG vaccination policies and practices","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0010","unstructured":"World Health Organization. Global Tuberculosis Control: WHO Report 2011. Geneva."},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0015","doi-asserted-by":"crossref","first-page":"e17984","DOI":"10.1371\/journal.pone.0017984","article-title":"The tuberculin skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an adolescent cohort study in South Africa","volume":"6","author":"Mahomed","year":"2011","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.vaccine.2014.04.084_bib0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1098\/rsif.2007.1138","article-title":"Eliminating human tuberculosis in the twenty-first century","volume":"5","author":"Dye","year":"2008","journal-title":"J R Soc Interface"},{"issue":"33","key":"10.1016\/j.vaccine.2014.04.084_bib0025","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines: drugs, and diagnostics","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc Nat Acad Sci USA"},{"issue":"42","key":"10.1016\/j.vaccine.2014.04.084_bib0030","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2014.04.084_bib0035","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.vaccine.2014.04.084_bib0040","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2014.04.084_bib0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1164\/rccm.200701-084OC","article-title":"Regulatory T cells depress immune responses to protective antigens in active tuberculosis","volume":"176","author":"Hougardy","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0050","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.134.3.713","article-title":"Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes","volume":"134","author":"Armstrong","year":"1971","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.vaccine.2014.04.084_bib0055","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1073\/pnas.0409716102","article-title":"Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis","volume":"102","author":"Vergne","year":"2005","journal-title":"Proc Nat Acad Sci USA"},{"issue":"5678","key":"10.1016\/j.vaccine.2014.04.084_bib0060","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1099384","article-title":"Protein kinase G from pathogenic mycobacteria promotes survival within macrophages","volume":"304","author":"Walburger","year":"2004","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.vaccine.2014.04.084_bib0065","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.4049\/jimmunol.153.6.2568","article-title":"Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages","volume":"153","author":"Xu","year":"1994","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2014.04.084_bib0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of tuberculosis in bacille Calmette-Guerin-primed: HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"Aids"},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000163633","article-title":"New insights into the immunopathology of tuberculosis","volume":"59","author":"Rook","year":"1991","journal-title":"Pathobiology"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0080","first-page":"239","article-title":"The Koch phenomenon and the immunopathology of tuberculosis","volume":"215","author":"Rook","year":"1996","journal-title":"Curr Top Microbiol Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2014.04.084_bib0085","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.vaccine.2009.12.083","article-title":"The second Geneva Consensus: recommendations for novel live TB vaccines","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2014.04.084_bib0090","first-page":"717","article-title":"Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong","volume":"5","author":"Leung","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9019","key":"10.1016\/j.vaccine.2014.04.084_bib0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(96)02166-6","article-title":"Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi","volume":"348","author":"Karonga Prevention Trial Group","year":"1996","journal-title":"Lancet"},{"issue":"8794","key":"10.1016\/j.vaccine.2014.04.084_bib0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0140-6736(92)90794-4","article-title":"Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi","volume":"339","author":"Ponnighaus","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0105","first-page":"27","article-title":"BCG vaccine. WHO position paper","author":"World Health Organization","year":"2004","journal-title":"Wkly Epidemiol Rec"},{"issue":"9493","key":"10.1016\/j.vaccine.2014.04.084_bib0110","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"Rodrigues","year":"2005","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.vaccine.2014.04.084_bib0115","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.vaccine.2011.05.023","article-title":"Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial","volume":"29","author":"Barreto","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0120","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1086\/314074","article-title":"Management of adverse reactions to bacille Calmette-Guerin vaccine","volume":"31","author":"FitzGerald","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2014.04.084_bib0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1086\/515201","article-title":"Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination","volume":"28","author":"Hoft","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0130","first-page":"1","article-title":"Tuberculosis prevention Trial, Madras","volume":"72","author":"Baily","year":"1980","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1086\/499311","article-title":"Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens","volume":"193","author":"Wilkinson","year":"2006","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2014.04.084_bib0140","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2014.04.084_bib0145","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis","volume":"54","author":"Andrews","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2014.04.084_bib0150","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/infdis\/jir162","article-title":"Epidemiologic inference from the distribution of tuberculosis cases in households in Lima: Peru","volume":"203","author":"Brooks-Pollock","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0155","series-title":"The South African tuberculosis control programme practical guidelines 2000","author":"National Tuberculosis Control Programme (NTCP)","year":"2000"},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0160","first-page":"310","article-title":"Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection","volume":"10","author":"Mahomed","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0165","first-page":"331","article-title":"Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa","volume":"15","author":"Mahomed","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2014.04.084_bib0175","first-page":"399","article-title":"Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren","volume":"7","author":"Dourado","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2014.04.084_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-1157(83)80040-7","article-title":"A comparative study of Danish (Statens Seruminstitut): Glaxo and Behringwerke vaccines\u2014revaccination of schoolchildren","volume":"11","author":"Bottiger","year":"1983","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0185","unstructured":"Global Tuberculosis Programme and Global Programme on Vaccines, Statement on BCG revaccination for the prevention of tuberculosis. Wkly Epidemiol Rec 1995:229\u2013231."},{"key":"10.1016\/j.vaccine.2014.04.084_bib0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(96)02166-6","article-title":"Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi","volume":"348","author":"Karonga Prevention Trial Group","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2014.04.084_bib0195","first-page":"1376","article-title":"Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants","volume":"12","author":"Hesseling","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2014.04.084_bib0200","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine: MVA85A, in healthy adults in South Africa","volume":"198","author":"Hawkridge","year":"2008","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2014.04.084_bib0205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A: a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2014.04.084_bib0210","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1164\/rccm.201108-1548OC","article-title":"A phase IIa trial of the new tuberculosis vaccine: MVA85A, in HIV- and\/or Mycobacterium tuberculosis-infected adults","volume":"185","author":"Scriba","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2014.04.084_bib0215","first-page":"CD006418","article-title":"Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children","volume":"1","author":"Gray","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2014.04.084_bib0220","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1378\/chest.13-1232","article-title":"Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study","volume":"145","author":"Johnson","year":"2014","journal-title":"Chest"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:58:46Z","timestamp":1689209926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14006355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":43,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0264410X14006355"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}